Nutra Pharma Net Loss Triples to $1.4M in Q1 2025 Despite Revenue Jump
Nutra Pharma Corp. posted a net loss of $1.4 million for the three months ending March 31, more than triple the $426,934 loss in the same period last year. Revenue nearly doubled to $73,974 from $37,732 in the prior-year quarter.
Nutra Pharma Corp., a California-based pharmaceutical company, reported a net loss of $1.4 million for the three months ending March 31, 2025, compared with a loss of $426,934 in the first quarter of 2024. The widening loss came despite a 96% increase in revenue, which climbed to $73,974 from $37,732 in the year-ago period. Read more earnings reports.
Operating expenses surged 27% to $418,150 from $330,506 in the prior-year quarter, outpacing the revenue gains. Cost of goods sold rose to $37,063 from $22,484, yielding a gross profit of $68,331 compared with $35,197 a year earlier. The company posted an operating loss of $349,819, wider than the $295,309 operating loss in the first quarter of 2024.
Cash used in operations totaled $405,006 for the quarter, more than double the $171,199 consumed in the same period last year. The company raised $408,454 from financing activities to cover the cash burn. Cash used in investing activities was $26,052.
Total liabilities climbed to $17.0 million as of March 31, 2025, up from $15.4 million at year-end 2024. Current liabilities accounted for $16.8 million of the total. The company held $775,179 in total assets at quarter-end, compared with $599,495 at December 31, 2024.
Stockholders' deficit widened to $16.2 million from $14.8 million at the end of 2024. Retained deficit stood at $77.6 million as of March 31, 2025, compared with $76.2 million three months earlier. The company had 7.1 billion common shares outstanding at quarter-end.
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $73,974 | $37,732 |
| Cost of Goods Sold | $37,063 | $22,484 |
| Gross Profit | $68,331 | $35,197 |
| Operating Expenses | $418,150 | $330,506 |
| Operating Loss | ($349,819) | ($295,309) |
| Net Loss | ($1,404,923) | ($426,934) |
| Cash from Operations | ($405,006) | ($171,199) |
The company reported basic and diluted earnings per share of $0.00 in both periods, based on a weighted average of 7.7 billion shares outstanding in the first quarter of 2025 and 7.6 billion shares in the year-ago quarter.